Document Detail


Prevention of cerebral vasospasm by vasodilatory peptide maxadilan following subarachnoid hemorrhage in rabbits.
MedLine Citation:
PMID:  9685937     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Maxadilan is a vasodilatory peptide isolated from the blood-feeding sand fly Lutzomyia longipalpis. Its vasodilatory activity, estimated by the formation of erythema on rabbit skin, is greater than those of calcitonin gene-related peptide, vasoactive intestinal polypeptide and pituitary adenylyl cyclase activating polypeptide (PACAP). We have recently demonstrated that maxadilan is a specific agonist for the PACAP type I receptor, which is widely distributed in brain. Therefore, we were interested in the vasodilatory effect of maxadilan on cerebral arteries and the possibility of its clinical use for the delayed cerebral vasospasm following subarachnoid (SAH). In the first experiment, 10(-10) mol/kg of maxadilan (in sterile water) was injected into the cisterna magna three days after the induction of experimental SAH in rabbits (n = 6). Maxadilan dilated spastic basilar arteries within 30 min of the injection, but not at 6 h. In the second experiment, to prolong the vasodilatory effect of maxadilan, tablets containing stearic acid, hydrogenated oil, lactose, hydroxypropylcellulose and 15 mg of maxadilan were prepared. In vitro testing showed that 60% of maxadilan could be released slowly within the initial five days. In vivo experiments were performed to implant the maxadilan tablet (n = 7) and the placebo tablet (n = 6) into the cisterna magna after the induction of experimental SAH in rabbits. The spastic response of the basilar artery was maximum on day three in the placebo-treated groups. In contrast, we observed no significant change in the arterial diameter until day five in the rabbits treated with maxadilan tablet. These data suggest that maxadilan may have therapeutic potency in treating cerebral vasospasm.
Authors:
T Kaminuma; H Shimizu; I Ahmad; N Ochiai; R Ehama; M Ohnuma; T Banba; K Watabe; E A Lerner; S Imaizumi; M Tajima; T Yoshimoto
Related Documents :
17453507 - Dynamic susceptibility contrast perfusion magnetic resonance imaging in patients with s...
6851277 - The pathology of hypertension in a tropical environment.
17913347 - Bilateral cerebellar infarction in the medial branches of posterior inferior cerebellar...
15511657 - Effects of handedness and gender on macro- and microstructure of the corpus callosum an...
2148167 - Clinical profile of patients with chagas' disease before and during sustained ventricul...
23346437 - Hypertrophic cardiomyopathy due to mitochondrial disease: prenatal diagnosis, managemen...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of controlled release : official journal of the Controlled Release Society     Volume:  52     ISSN:  0168-3659     ISO Abbreviation:  J Control Release     Publication Date:  1998 Mar 
Date Detail:
Created Date:  1998-08-13     Completed Date:  1998-08-13     Revised Date:  2004-02-09    
Medline Journal Info:
Nlm Unique ID:  8607908     Medline TA:  J Control Release     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  71-80     Citation Subset:  IM    
Affiliation:
Shiseido Research Center, Yokohama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Insect Proteins / administration & dosage,  therapeutic use*
Ischemic Attack, Transient / prevention & control*
Male
Rabbits
Subarachnoid Hemorrhage / drug therapy*
Vasodilator Agents
Chemical
Reg. No./Substance:
0/Insect Proteins; 0/Vasodilator Agents; 135374-80-0/maxadilan protein, insect

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Image analysis studies of water transport and dimensional changes occurring in the early stages of h...
Next Document:  Microparticle resins as a potential nasal drug delivery system for insulin.